Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 29 2023 - 6:30AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO,
and Co-Founder will present at NobleCon19 – Noble Capital Markets’
Nineteenth Annual Emerging Growth Equity Conference at Florida
Atlantic University, Executive Education Complex, in Boca Raton,
FL—taking place December 3 - 5, 2023.
Details regarding the presentation and moderated Q&A are as
follows:
Date: Monday, December 4, 2023
Location: Presentation Room 1
Time: 2 p.m. ET
Following the presentation, there will be an opportunity to meet
with the Company’s management team in a breakout session at
2:30 p.m. ET—Breakout Table 1 (located directly
across from the presentation room). Also, Ocugen will conduct
one-on-one meetings with registered investors to showcase the
Company’s business and clinical development strategy across its
unique gene therapy, cell therapy, and vaccine platforms, and
highlight recent corporate and pipeline-related achievements.
A webcast of the presentation will be available the following
day in the Events section of the Company’s website and as part of a
complete catalog of presentations available at Noble Capital
Markets’ Conference website and on Channelchek—the investor
portal created by Noble. The webcast will be archived on the
Company's website, the NobleCon website, and on Channelchek.com for
90 days following the event.
About Ocugen, Inc. Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patients’ lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations. These and other risks and uncertainties
are more fully described in our periodic filings with the
Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact: Tiffany Hamilton Head of
Communications Tiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2024 to Jun 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Jun 2023 to Jun 2024